SGN-ALPV is under clinical development by Seagen and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase I drugs for Endometrial Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SGN-ALPV’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SGN-ALPV is under development for the treatment of solid tumors, ovarian cancer, endometrial cancer, non-small cell lung cancer (NSCLC), gastric cancer, gastroesophageal junction carcinomas, cervical cancer, malignant testicular germ cell tumor and hematological malignancies. It is administered through intravenous route. It is an antibody drug conjugate (ADC). It acts by targeting cells expressing alkaline phosphatase placental type (ALPP) and alkaline phosphatase placental-like 2 (ALPPL2).
Seagen, formerly Seattle Genetics, is a biotechnology company focused on the discovery, development, and commercialization of monoclonal antibody-based therapies for the treatment of cancer. The company markets antibody-drug conjugates (ADCs) designed to target specific types of cancer. These includes Adcetris (brentuximab vedotin), for the treatment of Hodgkin’s lymphoma, T-cell lymphomas, and CD30 expressing lymphomas; Padcevtm (enfortumab vedotin-ejfv) for metastatic urothelial cancers; Tukysa (tucatinib) for the treatment of metastatic HER2-positive breast cancers, and Tivdak (tisotumab vedotin-tftv) for the treatment of certain metastatic cervical cancers. The company’s pipeline consists of novel therapies for addressing the unmet medical needs in blood-related cancers and solid tumors. Seagen products and pipeline are based on ADC technology and SEA technology which targets monoclonal antibodies and delivers agents for killing cancer cells. The company sells its products through specialty distributors. Seagen is headquartered in Bothell, Washington, the US.
For a complete picture of SGN-ALPV’s drug-specific PTSR and LoA scores, buy the report here.